194 related articles for article (PubMed ID: 25715772)
1. Pazopanib for Non-small Cell Lung Cancer: The First Case Report in Korea.
Jo J; Kim JH; Kim JY; Hyun C; Rhee J; Kwon J; Han S; Kim W
Cancer Res Treat; 2016 Jan; 48(1):393-7. PubMed ID: 25715772
[TBL] [Abstract][Full Text] [Related]
2. Pazopanib for the treatment of metastatic renal cell carcinoma.
Pick AM; Nystrom KK
Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
[TBL] [Abstract][Full Text] [Related]
3. Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma.
Sonpavde G; Hutson TE; Sternberg CN
Expert Opin Investig Drugs; 2008 Feb; 17(2):253-61. PubMed ID: 18230058
[TBL] [Abstract][Full Text] [Related]
4. A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma.
Kim MJ; Park SH; Lee JL; Lee SH; Lee SJ; Lim HY
BMC Urol; 2016 Aug; 16(1):46. PubMed ID: 27484998
[TBL] [Abstract][Full Text] [Related]
5. Pazopanib: an orally administered multi-targeted tyrosine kinase inhibitor for locally advanced or metastatic renal cell carcinoma.
Koc G; Wang X; Luo Y
Can J Urol; 2011 Dec; 18(6):5991-7. PubMed ID: 22166325
[TBL] [Abstract][Full Text] [Related]
6. Good tolerability, long-term survival and easy management of side effects in a patient with metastatic renal cell carcinoma treated with pazopanib.
Frascaroli M; Di Cesare P
Tumori; 2014; 100(6):e301-4. PubMed ID: 25688516
[TBL] [Abstract][Full Text] [Related]
7. An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study.
Mosca A; De Giorgi U; Procopio G; Basso U; Cartenì G; Bersanelli M; Naglieri E; Galli L; Caffo O; Fornarini G; Boccardo F; Porta C
Jpn J Clin Oncol; 2021 Mar; 51(3):484-491. PubMed ID: 33212499
[TBL] [Abstract][Full Text] [Related]
8. Pazopanib: in advanced renal cell carcinoma.
Sanford M; Keating GM
BioDrugs; 2010 Oct; 24(5):279-86. PubMed ID: 20649181
[TBL] [Abstract][Full Text] [Related]
9. Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study).
Schmidinger M; Bamias A; Procopio G; Hawkins R; Sanchez AR; Vázquez S; Srihari N; Kalofonos H; Bono P; Pisal CB; Hirschberg Y; Dezzani L; Ahmad Q; Jonasch E;
Oncologist; 2019 Apr; 24(4):491-497. PubMed ID: 30867244
[TBL] [Abstract][Full Text] [Related]
10. Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma.
McAlister RK; Aston J; Pollack M; Du L; Koyama T; Chism DD
Oncologist; 2018 Jun; 23(6):686-692. PubMed ID: 29487220
[TBL] [Abstract][Full Text] [Related]
11. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.
Hainsworth JD; Rubin MS; Arrowsmith ER; Khatcheressian J; Crane EJ; Franco LA
Clin Genitourin Cancer; 2013 Sep; 11(3):270-5. PubMed ID: 23665131
[TBL] [Abstract][Full Text] [Related]
12. Pazopanib: a review of its use in the management of advanced renal cell carcinoma.
McCormack PL
Drugs; 2014 Jul; 74(10):1111-25. PubMed ID: 24935162
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.
Matrana MR; Bathala T; Campbell MT; Duran C; Shetty A; Teegavarapu P; Kalra S; Xiao L; Atkinson B; Corn P; Jonasch E; Tannir NM
BJU Int; 2016 Aug; 118(2):264-71. PubMed ID: 26573089
[TBL] [Abstract][Full Text] [Related]
14. Pazopanib for the treatment of renal cell carcinoma and other malignancies.
Sonpavde G; Hutson TE; Sternberg CN
Drugs Today (Barc); 2009 Sep; 45(9):651-61. PubMed ID: 19956806
[TBL] [Abstract][Full Text] [Related]
15. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer.
Altorki N; Lane ME; Bauer T; Lee PC; Guarino MJ; Pass H; Felip E; Peylan-Ramu N; Gurpide A; Grannis FW; Mitchell JD; Tachdjian S; Swann RS; Huff A; Roychowdhury DF; Reeves A; Ottesen LH; Yankelevitz DF
J Clin Oncol; 2010 Jul; 28(19):3131-7. PubMed ID: 20516450
[TBL] [Abstract][Full Text] [Related]
16. Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064).
O'Brien ME; Gaafar R; Hasan B; Menis J; Cufer T; Popat S; Woll PJ; Surmont V; Georgoulias V; Montes A; Blackhall F; Hennig I; Schmid-Bindert G; Baas P;
Eur J Cancer; 2015 Aug; 51(12):1511-28. PubMed ID: 26074395
[TBL] [Abstract][Full Text] [Related]
17. First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting.
Vogelzang NJ; Hackshaw MD; Hutson TE; Bhowmik D; Yap M; Rembert D; Jonasch E
Clin Genitourin Cancer; 2015 Jun; 13(3):210-7. PubMed ID: 25498215
[TBL] [Abstract][Full Text] [Related]
18. [First Hungarian experience with pazopanib therapy for patients with metastatic renal cancer].
Maráz A; Bodrogi I; Csejtei A; Dank M; Géczi L; Küronya Z; Mangel L; Petrányi A; Szûcs M; Bodoky G
Magy Onkol; 2013 Sep; 57(3):173-6. PubMed ID: 24107823
[TBL] [Abstract][Full Text] [Related]
19. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
Sternberg CN; Hawkins RE; Wagstaff J; Salman P; Mardiak J; Barrios CH; Zarba JJ; Gladkov OA; Lee E; Szczylik C; McCann L; Rubin SD; Chen M; Davis ID
Eur J Cancer; 2013 Apr; 49(6):1287-96. PubMed ID: 23321547
[TBL] [Abstract][Full Text] [Related]
20. Long-term response to pazopanib in an elderly man with mRCC. A case report.
D'Aniello C; Cavaliere C; Pisconti S; Facchini G
Tumori; 2014; 100(6):e305-8. PubMed ID: 25688517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
